- Home
- NITO vs CARM Comparison
NITO vs CARM Comparison
Compare NITO & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- CARM
- Stock Information
- Founded
- NITO 2009
- CARM 2016
- Country
- NITO Israel
- CARM United States
- Employees
- NITO N/A
- CARM N/A
- Industry
- NITO
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- NITO
- CARM Health Care
- Exchange
- NITO NYSE
- CARM Nasdaq
- Market Cap
- NITO 7.8M
- CARM 8.4M
- IPO Year
- NITO N/A
- CARM N/A
- Fundamental
- Price
- NITO $0.24
- CARM $0.42
- Analyst Decision
- NITO
- CARM Hold
- Analyst Count
- NITO 0
- CARM 5
- Target Price
- NITO N/A
- CARM $0.90
- AVG Volume (30 Days)
- NITO 1.2M
- CARM 42.1M
- Earning Date
- NITO 08-13-2025
- CARM 08-07-2025
- Dividend Yield
- NITO N/A
- CARM N/A
- EPS Growth
- NITO N/A
- CARM N/A
- EPS
- NITO N/A
- CARM N/A
- Revenue
- NITO $232,000.00
- CARM $19,964,000.00
- Revenue This Year
- NITO N/A
- CARM N/A
- Revenue Next Year
- NITO N/A
- CARM N/A
- P/E Ratio
- NITO N/A
- CARM N/A
- Revenue Growth
- NITO 24.74
- CARM 32.45
- 52 Week Low
- NITO $0.16
- CARM $0.14
- 52 Week High
- NITO $3.49
- CARM $1.90
- Technical
- Relative Strength Index (RSI)
- NITO 42.39
- CARM 52.02
- Support Level
- NITO $0.23
- CARM $0.41
- Resistance Level
- NITO $0.26
- CARM $0.56
- Average True Range (ATR)
- NITO 0.02
- CARM 0.13
- MACD
- NITO -0.00
- CARM -0.01
- Stochastic Oscillator
- NITO 14.95
- CARM 20.33
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.